Skip to main content

North East Hampshire & Farnham

From Senior Head of Quality Improvement:

1) Your plans for meeting the NHS England Libre policy

North East Hampshire and Farnham CCG  as part of the Frimley Health Integrated Care System will be implementing the NHS recommendations on the use of Flash Glucose Systems in patients who fulfil the NHS England criteria as verified by the specialist diabetes service within Frimley Health Foundation Trust. A patient pathway to obtain Flash Glucose Systems is currently being designed with consultants in the specialist diabetes service. Patients who are not currently under the care of the specialist diabetes service who may fulfil the criteria can be referred by their GP to the service for consideration for Flash Glucose Systems. Those patients already under the care of the specialist should wait to discuss Flash Glucose Systems at their next routine specialist appointment. A Frequently Asked Questions leaflet will be produced for patients. A Frimley Health Integrated Care System position statement on the use and prescribing of Flash Glucose Systems will be published very shortly.


2) How the Libre prescribing process will be handled? Will it be Red, Amber or Green listed?

The Flash Glucose Systems device will be classified as AMBER on the Joint Frimley Health Formulary as it should only be initiated by the diabetes specialist service (device plus starter sensor) with the ongoing prescribing undertaken by the patient’s GP.

Comments

Popular posts from this blog

Abbott dX 2022 Barcelona - "Make it Count"

For the past four years I've been invited by Abbott to a conference bringing together people with diabetes from across Europe to discuss various topics.  The first year I was meant to attend, it was my 'man v horse' year (the horse won!), so was unable to attend and then the pandemic hit so two further dX's were held virtually.  I was fortunate to be asked to present at last year's session.  This year's event was back in-person and held in Barcelona, coinciding with the latter part of the ATTD conference.   At this point, I must make it very clear - Abbott invited me to the 2022 European Diabetes Exchange forum (dX), that took place in Barcelona.  I attended this two-day event to connect and interact with inspirational and influential people in the diabetes community.  Abbott paid for my ticket and accommodation. #InvitedbyAbbott.  This is formal and it needs to be - I have not been required to do anything by Abbott as a result of my attendance and I hope that m

The CCG Project!

In order to find out the situation around the country for Libre prescribing now that the national policy has been published, I have made the decision to contact many of them to find out their plans.  I have arbitrarily chosen to contact all English CCGs that in December 2018 prescribed Libre via Primary Care to less than 5% of their population (and one specific request from a group member).  I had hoped this would be a small list, but there are 135 CCGs on the list.  I may have bitten off more than I can chew, but I'm committed to doing this and feeding back.  It worked before and hopefully this level of scrutiny will bring similar results. Below is a screenshot of the base document I am sending to each of the CCGs - it has some fields that are merge fields, so don't worry about the brackets and codes in the document (I found a typo, which has now been corrected too) .  The major piece of work with respect to this is finding the right person to contact.  However, I have s

July Update - CCGs Under Pressure!

The heat is unbearable in some parts, not only in the environment, but also hopefully the heat directed at the decision-makers in 'non-compliant' CCGs who are either refusing to accept that Libre is a revolutionary tool for many T1s or have agreed to fund, but then set crippling criteria. Latest Prescribing Data Progress in prescribing continues, with stabilisation in Scotland and a continuation of the steady rise in the other three countries of the UK.  The Wales May data should be out this week. As mentioned last month, the situation in Scotland is particularly promising and the excellent Edinburgh Centre for Endocrinology and the Scottish Health Technologies Group have published documents that should significantly help the Libre case.  These documents are based on the first six months of prescribing Libre. Healthcare Improvement Scotland Statement Flash Glucose Monitoring is associated with improved glycaemic control and quality of life in people with type 1 d